

STATE BOARD OF OPTOMETRY

2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course Approval Checklist

Title:
Provider Name:
☑Completed ApplicationOpen to all Optometrists?☑Yes☐NoMaintain Record Agreement?☑Yes☐No
☑Correct Application Fee
☑ Detailed Course Summary
☑ Detailed Course Outline
□ PowerPoint and/or other Presentation Materials Explanation letter attached
□Advertising (optional)
☑CV for EACH Course Instructor
 ✓ License Verification for Each Course Instructor Disciplinary History? □Yes ☑No

BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY

Receipt#

Beneficiary ID



STATE BOARD OF OPTOMETRY

2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834 P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov



CONTINUING EDUCATION COURSE APPROVAL **APPLICATION**

\$50 Mandatory Fee

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after - receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date.

Please type or print clearly.						
Course Title	Course Presentation Date					
REVIEW OF EYE Drops: Prostaglandins	09/17/2017					
	ontact Information					
Provider Name						
	g , mb _ast) (Middle)					
Provider Mailing Address						
Street 3160 J St. City Sacramento State CA Zip 95816						
Provider Email Address apineda a liangvision. com						
Will the proposed course be open to all California license	ed optometrists?					
Do you agree to maintain and furnish to the Board and/o of course content and attendance as the Board requires, from the date of course presentation?						
Course Instructor Information Please provide the information below and attach the curriculum vitae for <u>each</u> instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.						
Instructor Name						
	ast) (Middle)					
License Number <u>G</u> 69355	License Typemedical					
Phone Number (916) (441-7020	Email Address spineda a llangvision.com					
I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.						
	1.31.2017					
Signature of Course Provider	Date Form CE-01 Rev. 5/16					

				FOR	BOARD ONLY	USE
Course Title	Date(s) of Course	Instructor(s)/Lecturer(s)	CE Hours Requested	Approved	Disapproved	ID#
Toric IOL's	01/18/2017	KEITH LIANG, MD	2			
Corneal Cross-Linking	03/15/2017	KEITH LIANG, MD	2			
Review of Eye Drops: Prostaglandins	05/17/2017	KEITH LIANG, MD	2			
Aspheric vs. Non-Aspheric: Night Time Vision	07/19/2017	KEITH LIANG, MD	2			
Tecnis, Symphony & Crystalens AO	09/13/2017	KEITH LIANG, MD	2			
Wavefront Technology: Topography Guided Laser	11/15/2017	KEITH LIANG, MD	2			
Treatments for Macular Degeneration	05/07/2017	KEITH LIANG, MD	2			
Glaucoma: Decisions & Choices	05/07/2017	KEITH LIANG, MD	2			
Ocular Hypertension	11/12/2017	KEITH LIANG, MD	2			
Optical Coherence Tomography of Macula & Optic	11/12/2017	KEITH LIANG, MD	2			

COM	AITTEE	COMM	IENTS.



February 23, 2017

State Board of Optometry 2450 Del Paso Road, Suite 105 Sacramento, CA 95834

Dear Boards of Optometry,

Thank you for considering my request for CE approval. I was recently informed by Kristina Eklund that I need to provide a letter to explain why I am not able to provide presentation materials for the scheduled events in 2017. I feel that providing current information to our network of optometrist is very important. I gather presentation information from a variety of information sources- mainly current ophthalmic studies (articles) and ophthalmic meetings that I attend periodically through the year. The Power Point presentations are created from information gathered from ASCRS held in May and AAO conferences held in November; this ensures that the information provided is not only current, but the newest technology that we can offer in the United States.

I have prided myself in the ability to deliver quality information to my optometric network and I have been working with the Board of Optometry for many years to provide CE's. I ask that you strongly consider issuing Continuing Education credits for 2017 as I have many Optometrists who depend on what is offered at my office.

Thank you so much for your consideration.

Keith Liang, MD

Ophthalmologist

Sincerely



COURSE SUBJECT MATTER

<u>Toric IOL's</u> <u>Instructor:</u> Keith Liang, MD

Event Date: January 18, 2017

Toric IOL Staar and Alcon have added a new dimension to cataract surgery to correct Astigmatism. It has allowed for greater post operative satisfaction from patients. Review the preoperative criteria required for successful implantation of the lens. The surgical steps required for successful implantation of the lens in the correct axis.

Corneal Cross-Linking Instructor: Keith Liang, MD

Event Date: March 15, 2017

Corneal Cross-Linking (CXL) has been used to treat issues like keratoconus and corneal ectasia after LASIK surgery since 1997. *Keratoconus* is a vision disorder that occurs when the normally round cornea (the front part of the eye) becomes thin and irregular (cone) shaped. This abnormal shape prevents the light entering the eye from being focused correctly on the retina and causes distortion of vision. The goal is to educate the physical signs to manage these patients pre-operatively and post operatively.

Review of Eye Drops: Prostaglandins Instructor: Keith Liang, MD

Event Date: May 17, 2017

Travatan, Lumigan and Xalatan drops are the family of eye drops that are the primary treatment for glaucoma. The difference will be reviewed and indications for use in the ocular hypertensive and glaucoma patients will be discussed.

Aspheric versus Non-Aspheric: Night-time Vision Instructor: Keith Liang, MD

Event Date: July 19, 2017

The wavefront modified IOL that affect spherical aberration will be reviewed. The latest medical discussion on the lenses affect on improved night time vision will be discussed. Wavefront date both pre and post operatively will be reviewed.

ResTor, Symphony & Crystalens Instructor: Keith Liang, MD

Event Date: September 13, 2017

Premium IOL is gaining greater aceptance in the cataract population. How does an optometrist council his or her patients on these latest advances in IOL surgery. The ideal candidate for each type of lens will be reviewed. How to manage post operative expectations will be a key factor the success of these lenes.

Wavefront Technology: Topography Guided Laser: Instructor: Keith Liang, MD

Event Date: November 15, 2017

Nidek laser from Japan has the obly FDA approved topography guided excimer ablation in the United States. The CATZ sofeware and Final Fit program will be reviewed on problematic patient discussions.

OUTLINE

Review of Eye drops-Prostaglandins: Keith Liang, MD

1. Prostaglandin analog eye drops are considered first-line treatment for glaucoma. Currently, there are 3 different types available for this indication: Lumigan, Travatan, and Xalatan.

a. Lumigan

- i. Lumigan (bimatoprost) reduces pressure in the eye by increasing the amount of fluid that drains from the eye. Lumigan ophthalmic solution (eye drops) is used to treat open-angle glaucoma and other causes of high pressure inside the eyes. Lumigan may also be used for purposes not listed in this medication guide
- ii. Lumigan) is a synthetic prostamide analog with ocular hypotensive activity that works by regulating the flow of fluid within the eye to maintain a normal pressure. It is used to treat certain types of glaucoma and other causes of high pressure inside the eye.

b. Travatan

- i. Travatan is a prostaglandin analog. It works to reduce pressure in the eye by increasing the amount of fluid that drains from the eye. Travatan is used to treat increased pressure in the eye (ocular hypertension) and open-angle glaucoma in patients who cannot use or do not respond to other medicines.
- ii. Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs.
- iii. The updated solution, Travatan Z (travoprost ophthalmic solution) 0.004%, replaced benzalkonium chloride (BAK), a preservative commonly found in ophthalmic solutions, with Sofzia, an ionic buffered preservative that is gentler on the ocular surface.

c. Xalatan

- i. Xalatan is approved to treat high eye pressure, which may lead to glaucoma. Xalatan (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.
- ii. Latanoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Latanoprost is in a class of medications called prostaglandin analogs.

KEITH LIANG M.D.

CORNEAL, CATARACT, GLAUCOMA AND REFRACTIVE SURGEON

3160 J STREET SACRAMENTO, CA 95816–4403 (916) 446–2020 <u>kliang@liangvision.com</u>

PRIVATE PRACTICE

CENTER FOR SIGHT CLINIC AND LASER CENTER 1995 – Present

SACRAMENTO EYE SURGICENTER

Medical Director 1999 – Present

3150 J Street

Sacramento, CA 95816

EDUCATION

CHIEF RESIDENCY LSU – Lions Eye Center 1993 – 1994

Cornea and Refractive Surgery

New Orleans, Louisiana

RESIDENCY Louisiana State Univ. Medical Center

1990 - 1994

New Orleans, Louisiana

INTENRSHIP University of Southern California-

Los Angeles County Medical Center

1989 - 1990

Los Angeles, California

MEDICAL SCHOOL University of Southern California-

Keck School of Medicine

1985 - 1989

Los Angeles, California

UNDERGRADUATE University of California at Los Angeles

1982 - 1985

Los Angeles, California

MEMBERSHIPS

American Academy of Ophthalmology
American Board of Ophthalmology
American Society of Cataract and Refractive Surgery
International Society of Refractive Surgery
New Orleans Academy of Ophthalmology
Association for Research in Vision and Ophthalmology

PAPERS

"Introduction to the 13th NIDEK International Refractive Symposium: Cyberspace"
Journal of Refractive Surgery, Volume 25, January (Suppl) 2009

"Vision Quest" – By Reed Parsell/photography by 521Productions.com Sacramento Magazine, 174, 176–177, September 2007

"New NSAID Speeds Resolution of Corneal Ulcer" Ophthalmology Management 49–50, January 2006

"Acrysof Restor IOL Presbyopic lens removal and exchange" Cataract & Refractive Surgery Today Volume 6, No. 4: 66–69, April 2006

"Wavefront-Adjusted Treatments on the Nidek EC-5000" Cataract & Refractive Surgery Today 82-84, August 2004

"Cohesive viscoelastic offers predictable protection – Surgeon depends on high-viscosity agent for 95% of cataract cases" – By Lynda Charters, Reviewed by Keith Liang, M.D. Ophthalmology Times 34, February 15, 2003

"A Comparison of the Nidek EC-5000, Visx S2 and Summit Apex Lasers" Review of Ophthalmology Part 3 of 3: 6–7, July 2001

"Fungal Keratitis from Nylon Lawn Trimmers" American Journal of Ophthalmology 114:437–440, October 1992

"Browns Superior Oblique Tendon syndrome After Baerveldt Implant" Archives of Ophthalmology 110:1368, 1992

CLINICAL TRIALS

<u>CRS – NIDEK</u> Clinical treatment of Astigmatism IDE 1999 – 2000 <u>CLARITY Holos</u>-On going study to develop intraoperative aberrometry for Cataract Surgery. <u>ACOES Cross linking investigation</u>- evaluate efficacy of cornea collagen crosslinking in Keratoconus and Ectasia eyes

<u>CRS/ISRS – LASIK Clinical investigation:</u> Evaluate the efficacy of LASIK and submit data to FDA Device Committee 1996 – 1998

<u>CRS/ISRS – VISX</u> Clinical treatment of Astigmatism and high myopia IDE 1996 – 1997

NIDEK PRK Study Site – worked under supervision of Marguerite McDonald M.D. in New Orleans, LA – 1994

<u>AUTONOMOUS</u> – Preliminary monkey treatments at Tulane vivarium under the direction of Marguerite McDonald M.D. – 1994

PRESENTATIONS

AAO Intraoperative Aberrometry –HOLOS for refractive cataract surgery. IOL Predictor 2016

ASCRS Intraoperative Aberrometry –HOLOS for refractive cataract surgery 2015

ASCRS- Topography guided laser- How to use the CATZ and OATZ software to achieve optimal results- NIDEK 2014

AAO – Laser assisted Cataract Surgery- Femto LRI incisions with Lensar laser 2013

OPTOMETRIC – Semi-annual half-day lectures to local Optometrists regarding various topics in Ophthalmology – 1995 – 2009 – Sacramento, CA

OPTOMETRIC – Bi-monthly dinner lectures to local Optometrists regarding various topics in Ophthalmology – 1995 – 2009 – Sacramento, CA

CRS – How to remove a multifocal lens – December, 2007 – Las Vegas, NV

ASCRS – Akahoshi technique with the millennium system. Bausch & Lomb – 2005 Washington, D.C.

ASCRS – Nidek wavefront adjusted myopic treatments utilizing 6.5/7.5 zones compared to non–wavefront treatments – 2004 San Diego, CA

 \mathbf{ASCRS} – Combination Akahoshi pre-chop and flip technique for cataract surgery – 2001

 $\mathbf{ASCRS} - \mathbf{LASIK}$ Video Grand Rounds: Complications and Management-panel member -1999 - 2001

AAO – LASIK Video Grand Rounds: Complications and Management-panel member – 1999 – 2001

ASCRS – Comparison of NIDEK, VISX and Summit Lasers for the LASIK treatment of myopic astigmatism – 2000

ASCRS – Initial clinical pearls for the insertion of Starr Posterior ICL – a beginning surgeon's experience – 2000

ASCRS – Results of Mobile VISX Laser in the LASIK treatment of myopic astigmatism – 1999

FDA DEVICE PANEL – Gaithersburg, Maryland - presented LASIK data for FDA approval of LASIK procedure – 1998

LSU- New Orleans Academy- Pigmentary Dispersion Glaucoma-Peripheral Iridectomy- clinical trial of P.I. in myopic patients with posterior bowing of iris plane 1992

ARVO- Flourescein angiographic Histopathological Correlation of Dihematoporphyrin/Argon Laser Treated Vascualture & Subretina Neovasculariztion 1988

CERTIFICATION

2016- ALLEGRETTO WAVE EYE-Q 400HZ

2015 - HOLOS ABERROMETRY FOR CATARACT SURGERY

2014- ZIEMER S FEMTO LDV CRYSTALLINE-BLADE FREE

2013 - Glaucoma- ISTENT IMPLANT

2012 - LENSAR FEMTOSECOND LASER

2008 - Glaucoma - TRABECUTOME SURGERY

2007 – STAAR INTRAOCULAR CONTACT LENS

2007 - MULTIFOCAL REZOOM LENS

2007 – ASTIGMATISM LENS TORIC

2006 - MULTIFOCAL RESTORE LENS

2006 – VERISYSE INTRAOCULAR CONTACT LENS

2005 - Glaucoma - SELECTIVE LASER TRABECULOPLASY

2004 - ALLEGRETTO EXCIMER LASER SYSTEM

2004 – CRYSTALENS

2000 – LADAR VISION EXCIMER LASER SYSTEM

1999 – NIDEK EXCIMER LASER SYSTEM

1996 – VISX EXCIMER LASER SYSTEM

1995 – SUMMIT EXCIMER LASER SYSTEM

OUTLINE

Review of Eye drops-Prostaglandins: Keith Liang, MD

1. Prostaglandin analog eye drops are considered first-line treatment for glaucoma. Currently, there are 3 different types available for this indication: Lumigan, Travatan, and Xalatan.

a. Lumigan

- i. Lumigan (bimatoprost) reduces pressure in the eye by increasing the amount of fluid that drains from the eye. Lumigan ophthalmic solution (eye drops) is used to treat open-angle glaucoma and other causes of high pressure inside the eyes. Lumigan may also be used for purposes not listed in this medication guide
- ii. Lumigan) is a synthetic prostamide analog with ocular hypotensive activity that works by regulating the flow of fluid within the eye to maintain a normal pressure. It is used to treat certain types of glaucoma and other causes of high pressure inside the eye.

b. Travatan

- i. Travatan is a prostaglandin analog. It works to reduce pressure in the eye by increasing the amount of fluid that drains from the eye. Travatan is used to treat increased pressure in the eye (ocular hypertension) and open-angle glaucoma in patients who cannot use or do not respond to other medicines.
- ii. Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs.
- iii. The updated solution, Travatan Z (travoprost ophthalmic solution) 0.004%, replaced benzalkonium chloride (BAK), a preservative commonly found in ophthalmic solutions, with Sofzia, an ionic buffered preservative that is gentler on the ocular surface.

c. Xalatan

- Xalatan is approved to treat high eye pressure, which may lead to glaucoma.
 Xalatan (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.
- ii. Latanoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Latanoprost is in a class of medications called prostaglandin analogs.